Prognostic Impact of Fibroblast Growth Factor 21 in Patients With Heart Failure.

ABSTRACT:

Background

Systemic and cardiac metabolic disorders play a key role in patients with heart failure (HF). Fibroblast growth factor 21 (FGF21) is mainly secreted from the liver and has various effects on cardiomyocytes, including protection against oxidative stress, cardiac hypertrophy, and inflammation. However, the pathophysiologic and prognostic impact of FGF21 remains unknown.

Methods and results

Serum levels of FGF21 and echocardiography were performed in patients with compensated HF (n=162) and control patients without HF (n=20). Compared with the control patients, those with HF displayed higher FGF21 levels (100 [76-213] vs. 237 [135-575] pg/mL; P=0.0006). There were no or modest correlations of FGF21 levels with clinical variables and echocardiographic parameters. Duri

SUBMITTER: Sunaga H 

PROVIDER: S-EPMC12510960 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature